Loading
companiesCompany
SARC (Sarcoma Alliance for Research through Collaboration)
aka Sarcoma Alliance for Research through Collaboration, SARC
SARC is a US non-profit sarcoma research organisation founded in 2003 by sarcoma physicians at five medical centres to run collaborative trials; in OnCo it leads SARC028, the pembrolizumab study across sarcoma subtypes.
Overview
SARC (Sarcoma Alliance for Research through Collaboration) is a US 501(c)(3) non-profit cancer research organisation dedicated to research for the prevention, treatment and cure of sarcoma; it was formed in 2003 by a core group of medical and paediatric sarcoma experts at five major medical facilities, received a National Cancer Institute SPORE grant in 2012, and gives its address as P.O. Box 406, Ann Arbor, Michigan (sarctrials.org). ClinicalTrials.gov names it lead sponsor (OTHER class, with Merck Sharp & Dohme as collaborator) of SARC028 (NCT02301039, phase 2, pembrolizumab in advanced soft tissue and bone sarcoma), the trial recorded in OnCo. It has no products of its own.
Similar pages
not linked directly; found by shared links- CompanyItalian Sarcoma Group
Shares Undifferentiated pleomorphic sarcoma (UPS), Sarcomas (soft tissue, bone, GIST) and the tag cooperative-group.
- CompanyFrench Sarcoma Group
Shares Ewing sarcoma, Osteosarcoma, Sarcomas (soft tissue, bone, GIST) and the tag cooperative-group.
- CompanyScandinavian Sarcoma Group
Shares Sarcomas (soft tissue, bone, GIST) and the tag cooperative-group.
- CompanyAIO (Arbeitsgemeinschaft Internistische Onkologie)
Shares Sarcomas (soft tissue, bone, GIST) and the tag cooperative-group.
- Key paperSARC028: pembrolizumab in advanced soft tissue and bone sarcoma
- TargetDDIT3
- TargetACSL6
- PersonStefan S. Bielack
Shares Osteosarcoma and the tag cooperative-group.